Matthew Lang
General Counsel bei LYELL IMMUNOPHARMA, INC.
Profil
Matthew Lang is currently the Secretary, Chief Legal & Business Officer at Lyell Immunopharma, Inc. He previously worked as the Chairman-Management Board at Myovant Sciences GmbH, Director at United Way of the Bay Area, VP & Head- Global Litigation & Investigations at Gilead Sciences, Inc., and Attorney at Dechert LLP.
He also held positions as Secretary, Chief Administrative & Legal Officer at Myovant Sciences, Inc. and General Counsel at Myovant Sciences Ltd.
Lang received his undergraduate degree from Queen's University in 1999 and his graduate degree from The University of Pennsylvania Law School in 2002.
Aktive Positionen von Matthew Lang
| Unternehmen | Position | Beginn |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | General Counsel | 05.07.2023 |
Ehemalige bekannte Positionen von Matthew Lang
| Unternehmen | Position | Ende |
|---|---|---|
United Way of the Bay Area
 United Way of the Bay Area Miscellaneous Commercial ServicesCommercial Services United Way of the Bay Area owns and operates charities. The company was founded in 1923 and is headquartered in San Francisco, CA. | Director/Board Member | 01.01.2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.07.2017 |
Dechert LLP
 Dechert LLP Miscellaneous Commercial ServicesCommercial Services Dechert LLP provides legal services. It serves the chemical, construction, finance and real estate, energy, insurance, and health sectors. The firm's practice areas include business restructuring and reorganization, commercial litigation, corporate and securities, energy, finance and real estate, financial services, mergers and acquisitions, and private equity. The company was founded in 1875 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | 01.01.2009 |
Myovant Sciences GmbH
 Myovant Sciences GmbH BiotechnologyHealth Technology Myovant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company is headquartered in Basel, Switzerland. | Chief Executive Officer | - |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Chief Administrative Officer | - |
Ausbildung von Matthew Lang
| Queen's University | Undergraduate Degree |
| The University of Pennsylvania Law School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Dechert LLP
Dechert LLP Miscellaneous Commercial ServicesCommercial Services Dechert LLP provides legal services. It serves the chemical, construction, finance and real estate, energy, insurance, and health sectors. The firm's practice areas include business restructuring and reorganization, commercial litigation, corporate and securities, energy, finance and real estate, financial services, mergers and acquisitions, and private equity. The company was founded in 1875 and is headquartered in Philadelphia, PA. | Commercial Services |
United Way of the Bay Area
United Way of the Bay Area Miscellaneous Commercial ServicesCommercial Services United Way of the Bay Area owns and operates charities. The company was founded in 1923 and is headquartered in San Francisco, CA. | Commercial Services |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Myovant Sciences GmbH
Myovant Sciences GmbH BiotechnologyHealth Technology Myovant Sciences GmbH engages in the development and marketing of biopharmaceutical products. The company is headquartered in Basel, Switzerland. | Health Technology |
